Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986231 crossover echocardiography study in chronic heart failure
NL-OMON46654Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of cimlanod in heart failure (HF) and heart failure with reduced ejection fraction (HFrEF) (6 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Mean stroke volume index versus placebo. Started Jun 2018; status: completed.
02
Drugs
cimlanod
03
Conditions
heart failure (HF)heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NL-OMON46654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46654.